OKYO Pharma announced additional key findings from analyses of the clinical data set from the 240 patient Phase 2, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of OK-101 ophthalmic solution in patients with DED. These new findings include: a statistically significant and durable reduction in ocular pain; statistically significant improvement in Tear Film Break-Up Time throughout the study – a clinically important endpoint; multiple symptomatic improvements as observed by both data obtained from patient clinic visits as well as data from patient daily symptom diaries
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
- OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
- Okyo Pharma to release new data from Phase 2 dry eye disease trial
- Okyo Pharma price target raised to $6 from $5 at H.C. Wainwright
- OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
